Intellia Therapeutics' stock surged 5.02% during Thursday's intraday trading session.
The significant price increase appears to be driven by news that Cathie Wood's ARK Investment purchased 2.4 million shares of the gene-editing company. Such a substantial acquisition by a prominent institutional investor typically signals strong confidence in the company's prospects and generates positive market sentiment.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.